Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.00 +0.85 (+1.88%)

Streaming Delayed Price Updated: 12:34 PM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

42 43 Next >

Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients ↗

March 07, 2025

Eli Lilly's Ebglyss showed sustained eczema relief, with 50% achieving full skin clearance and 87% maintaining near-clear skin over three years.

Via Benzinga

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗

March 03, 2025

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.

Via Benzinga

For those who appreciate value investing, SANOFI-ADR (NASDAQ:SNY) is a compelling option with its solid fundamentals. ↗

March 03, 2025

When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

Is SANOFI-ADR (NASDAQ:SNY) Ready to Break Out of Its Range? ↗

February 28, 2025

Investors are keeping a close eye on SANOFI-ADR (NASDAQ:SNY) as it boasts an impressive technical rating of 8 out of 10, signaling a possible breakout.

Via Chartmill

Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership ↗

February 27, 2025

The company expects to generate $300 million to $350 million in adjusted licensing, royalties, and other revenue in 2025.

Via Stocktwits

Is NASDAQ:SNY suited for dividend investing? ↗

February 26, 2025

Is SANOFI-ADR (NASDAQ:SNY) suited for dividend investing?

Via Chartmill

How Is The Market Feeling About Sanofi? ↗

February 14, 2025

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

January 24, 2025

Via Benzinga

Price Over Earnings Overview: Sanofi ↗

January 10, 2025

Via Benzinga

Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds ↗

February 27, 2025

Moderna is under pressure as two of its vaccines hit potential snags.

Via Investor's Business Daily

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value ↗

February 27, 2025

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.

Via Benzinga

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

February 27, 2025

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Via MarketBeat

Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples ↗

February 27, 2025

Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax.

Via Stocktwits

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease ↗

February 24, 2025

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

December 30, 2024

Via Benzinga

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

February 22, 2025

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes ↗

February 18, 2025

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Via Benzinga

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study ↗

February 13, 2025

Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.

Via Benzinga

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗

February 06, 2025

The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.

Via Investor's Business Daily

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday ↗

February 04, 2025

Via The Motley Fool

Sanofi Buys Back ~$3 Billion In Shares From L'Oréal: Details ↗

February 03, 2025

Sanofi has purchased 2.3% of its shares from L'Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected...

Via Benzinga

Sanofi (SNY) Q4 2024 Earnings Call Transcript ↗

January 30, 2025

SNY earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data ↗

January 28, 2025

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.

Via Benzinga

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm? ↗

January 28, 2025

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald...

Via Benzinga

Topics Government

Earnings Scheduled For January 30, 2025 ↗

January 30, 2025

Via Benzinga

Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses ↗

January 22, 2025

FDA issues warning letter to Sanofi over its Genzyme facility, citing process deviations, equipment issues, and quality oversight lapses.

Via Benzinga

AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion ↗

January 18, 2025

Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,...

Via Talk Markets

Topics Artificial Intelligence Stocks / Equities

Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week ↗

January 16, 2025

The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer.

Via Investor's Business Daily

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma ↗

January 09, 2025

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

Via Benzinga

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗

January 08, 2025

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

Via Benzinga

Topics ETFs

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.